The American Psychiatric Association (APA) has updated its Privacy Policy and Terms of Use, including with new information specifically addressed to individuals in the European Economic Area. As described in the Privacy Policy and Terms of Use, this website utilizes cookies, including for the purpose of offering an optimal online experience and services tailored to your preferences.

Please read the entire Privacy Policy and Terms of Use. By closing this message, browsing this website, continuing the navigation, or otherwise continuing to use the APA's websites, you confirm that you understand and accept the terms of the Privacy Policy and Terms of Use, including the utilization of cookies.

×
Letter to the EditorFull Access

Hypersalivation Coincident With Olanzapine Treatment

Published Online:https://doi.org/10.1176/ajp.155.7.993a

TO THE EDITOR: Drooling, often manifested as pillow wetting during sleep, is a common adverse effect of the atypical antipsychotic clozapine (1). In light of clozapine's propensity to cause anticholinergic effects, it is surprising that patients complain of drooling rather than of dry mouth—the expected salivary anticholinergic response.

Olanzapine, a derivative of clozapine, is an atypical antipsychotic with a receptor-binding profile similar to that of clozapine (2). To our knowledge, there are no published descriptions besides the following one of drooling as a side effect of olanzapine treatment.

Ms. A was a 20-year-old Caucasian woman with a 3-year history of schizophrenia. After an initial 4-week trial of olanzapine, 10 mg/day, with substantial clinical improvement, she was treated solely with olanzapine, 15 mg/day. Her early spontaneous complaints of adverse effects included experiencing morning grogginess and soaking her pillow with saliva during sleep. When we increased her olanzapine dose to 15 mg/day, her morning grogginess and pillow wetting worsened. A physical examination revealed a normal gait and no muscular rigidity.

Among patients treated with antipsychotics, parkinsonism-related drooling is due to throat muscle rigidity and a resultant decrease in saliva swallowing. With clozapine, drooling and pillow wetting presumably result from increased saliva production (hence, the usual descriptors, “hypersalivation” and “sialorrhea”), although the mechanism has not been definitively demonstrated. It is unlikely that Ms. A's drooling was related to parkinsonism because she had no extrapyramidal symptoms.

Two proposed mechanisms for clozapine-induced hypersalivation may be relevant here (35). Increased saliva production results from salivary sympathetic α-adrenergic receptor antagonism or from parasympathetic cholinergic (muscarinic) receptor agonism. Ms. A's sialorrhea may have been a result of olanzapine's potent α-adrenergic antagonism. Alternatively, sialorrhea may stem from stimulation of salivary muscarinic receptors. Both clozapine and olanzapine have high affinity for the five muscarinic receptors (M1–M5), and both are antagonists at M1–M3 and M5, consistent with anticholinergic effects. Clozapine (4, 5) and olanzapine (5) are reported to be agonists or partial agonists at M4 receptors. This explanation is speculative because the importance of M4 receptors in human saliva production is unknown.

While the cause of pillow wetting for Ms. A as well as clozapine-treated patients is not understood, anticholinergic and adrenergic agonist therapies are used for clozapine-induced pillow wetting (1, 3). Although Ms. A declined pharmacological treatment, she welcomed discussion of nonpharmacological management (e.g., covering her pillow with a towel or sleeping on her side propped up with extra pillows). Physicians should monitor patients treated with olanzapine for this potentially troublesome adverse effect.

References

1 Safferman A, Lieberman JA, Kane JM, Szymanski S, Kinon B: Update on the clinical efficacy and side effects of clozapine. Schizophr Bull 1991; 177:247–261CrossrefGoogle Scholar

2 Moore NA, Calligara DO, Wong DT, Bymaster F, Tye N: The pharmacology of olanzapine and other new antipsychotic agents. Curr Opin Invest Drugs 1993; 2:281–293Google Scholar

3 Grabowski J: Clonidine treatment of clozapine-induced hypersalivation. J Clin Psychopharmacol 1992; 12:69–70Crossref, MedlineGoogle Scholar

4 Zorn SH, Jones SB, Ward KM, Liston DR: Clozapine is a potent and selective muscarinic M4 receptor agonist. Eur J Pharmacol 1994; 269:R1–2Google Scholar

5 Zeng XP, Le F, Richelson E: Muscarinic m4 receptor activation by some atypical antipsychotic drugs. Eur J Pharmacol 1997; 321:349–354Crossref, MedlineGoogle Scholar